{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:44:53Z","timestamp":1778539493659,"version":"3.51.4"},"reference-count":26,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2020.8629","type":"journal-article","created":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T08:59:37Z","timestamp":1585645177000},"source":"Crossref","is-referenced-by-count":3,"title":["PTEN inhibitor VO\u2011OHpic suppresses TSC2\u2011\/\u2011 MEFs proliferation by excessively inhibiting autophagy via the PTEN\/PRAS40 pathway"],"prefix":"10.3892","author":[{"given":"Wenda","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yushi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanzhong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2020,3,31]]},"reference":[{"issue":"CD011272","key":"key20200713010442_b1-etm-0-0-8629","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011272.pub2","article-title":"Rapamycin and rapalogs for tuberous sclerosis complex","volume":"7","author":"Sasongko","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"key20200713010442_b2-etm-0-0-8629","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41581-018-0059-6","article-title":"Renal disease in tuberous sclerosis complex: Pathogenesis and therapy","volume":"14","author":"Lam","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"key20200713010442_b3-etm-0-0-8629","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.3111\/13696998.2015.1075995","article-title":"Kidney involvement in tuberous sclerosis complex: The impact on healthcare resource use and costs","volume":"18","author":"Vekeman","year":"2015","journal-title":"J Med Econ"},{"key":"key20200713010442_b4-etm-0-0-8629","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/ndt\/gfv249","article-title":"Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: Extension of a randomized controlled trial","volume":"31","author":"Bissler","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"43","key":"key20200713010442_b5-etm-0-0-8629","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0781-y","article-title":"Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: A two years trial","volume":"13","author":"Cai","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"key20200713010442_b6-etm-0-0-8629","doi-asserted-by":"publisher","first-page":"12455","DOI":"10.1073\/pnas.1104361108","article-title":"Tumorigenesis in tuberous sclerosis complex is autophagy and p62\/sequestosome 1 (SQSTM1)-dependent","volume":"108","author":"Parkhitko","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20200713010442_b7-etm-0-0-8629","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1089\/ars.2013.5371","article-title":"An overview of autophagy: Morphology, mechanism, and regulation","volume":"20","author":"Parzych","year":"2014","journal-title":"Antioxid Redox Signal"},{"key":"key20200713010442_b8-etm-0-0-8629","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF03402040","article-title":"The molecular mechanism of autophagy","volume":"9","author":"Wang","year":"2003","journal-title":"Mol Med"},{"key":"key20200713010442_b9-etm-0-0-8629","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/j.1750-3639.2012.00634.x","article-title":"Suppressed expression of autophagosomal protein LC3 in cortical tubers of tuberous sclerosis complex","volume":"23","author":"Miyahara","year":"2013","journal-title":"Brain Pathol"},{"key":"key20200713010442_b10-etm-0-0-8629","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/cr.2011.152","article-title":"Autophagy: For better or for worse","volume":"22","author":"Wirawan","year":"2012","journal-title":"Cell Res"},{"key":"key20200713010442_b11-etm-0-0-8629","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1172\/JCI28833","article-title":"Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma","volume":"117","author":"Amaravadi","year":"2007","journal-title":"J Clin Invest"},{"key":"key20200713010442_b12-etm-0-0-8629","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cell.2007.12.018","article-title":"Autophagy in the pathogenesis of disease","volume":"132","author":"Levine","year":"2008","journal-title":"Cell"},{"key":"key20200713010442_b13-etm-0-0-8629","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1172\/JCI73939","article-title":"mTOR: A pharmacologic target for autophagy regulation","volume":"125","author":"Kim","year":"2015","journal-title":"J Clin Invest"},{"issue":"E285","key":"key20200713010442_b14-etm-0-0-8629","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23020285","article-title":"PTEN inhibition in human disease therapy","volume":"23","author":"Pulido","year":"2018","journal-title":"Molecules"},{"key":"key20200713010442_b15-etm-0-0-8629","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1101\/gad.1699608","article-title":"Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events","volume":"22","author":"Nardella","year":"2008","journal-title":"Genes Dev"},{"key":"key20200713010442_b16-etm-0-0-8629","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1172\/JCI28984","article-title":"PDGFRs are critical for PI3K\/Akt activation and negatively regulated by mTOR","volume":"117","author":"Zhang","year":"2007","journal-title":"J Clin Invest"},{"key":"key20200713010442_b17-etm-0-0-8629","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jbior.2014.09.012","article-title":"PTEN inhibitors: An evaluation of current compounds","volume":"57","author":"Spinelli","year":"2015","journal-title":"Adv Biol Regul"},{"key":"key20200713010442_b18-etm-0-0-8629","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1042\/CS20150149","article-title":"Cellular and molecular effects of the mTOR inhibitor everolimus","volume":"129","author":"Saran","year":"2015","journal-title":"Clin Sci (Lond)"},{"key":"key20200713010442_b19-etm-0-0-8629","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.molcel.2016.01.013","article-title":"mTORC1 coordinates protein synthesis and immunoproteasome formation via PRAS40 to prevent accumulation of protein stress","volume":"61","author":"Yun","year":"2016","journal-title":"Mol Cell"},{"key":"key20200713010442_b20-etm-0-0-8629","first-page":"5645","article-title":"Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors","volume":"62","author":"Kenerson","year":"2002","journal-title":"Cancer Res"},{"key":"key20200713010442_b21-etm-0-0-8629","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1203\/01.PDR.0000147727.78571.07","article-title":"Effects of rapamycin in the Eker rat model of tuberous sclerosis complex","volume":"57","author":"Kenerson","year":"2005","journal-title":"Pediatr Res"},{"key":"key20200713010442_b22-etm-0-0-8629","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): A multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"key":"key20200713010442_b23-etm-0-0-8629","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): A multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"key":"key20200713010442_b24-etm-0-0-8629","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N Engl J Med"},{"key":"key20200713010442_b25-etm-0-0-8629","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.nbd.2014.02.006","article-title":"PRAS40 plays a pivotal role in protecting against stroke by linking the Akt and mTOR pathways","volume":"66","author":"Xiong","year":"2014","journal-title":"Neurobiol Dis"},{"key":"key20200713010442_b26-etm-0-0-8629","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.drudis.2016.04.005","article-title":"Targeting PRAS40 for multiple diseases","volume":"21","author":"Chong","year":"2016","journal-title":"Drug Discov Today"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:04:49Z","timestamp":1594598689000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2020.8629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,31]]},"references-count":26,"URL":"https:\/\/doi.org\/10.3892\/etm.2020.8629","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,31]]}}}